Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05061134 · ClinicalTrials.gov registry record · Phase 2

A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition

A Phase 2 study of Melanoma, sponsored by AstraZeneca.

Active
Registry status
Phase 2
Development phase
194
Enrollment target
20
Study locations

NCT05061134 is a Phase 2 study of Melanoma that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 194 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05061134, a Phase 2 study of Melanoma, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
194 participants
Enrollment target
20
Study locations

Study Summary

Main study: This is an open-label, phase 2 study that aims to evaluate the efficacy and safety/tolerability of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma and primary or secondary resistance to PD-(L)1 inhibition.

Conditions Studied

Melanoma

Interventions

  • BIOLOGICAL Durvalumab
  • DRUG Ceralasertib

Study Locations (20)

Other

  • Research Site - Darlinghurst
  • Research Site - East Melbourne
  • Research Site - Herston
  • Research Site - Woolloongabba
  • Research Site - Belgium
  • Research Site - Bruges
  • Research Site - Ghent
  • Research Site - Leuven
  • Research Site - Bobigny
  • Research Site - Boulogne-Billancourt

California

  • Research Site - Los Angeles
  • Research Site - Sacramento
  • Research Site - San Francisco

Ontario

  • Research Site - Toronto
  • Research Site - Toronto

Florida

  • Research Site - Tampa

Maryland

  • Research Site - Lutherville-Timonium

Tennessee

  • Research Site - Nashville

Alberta

  • Research Site - Edmonton

Quebec

  • Research Site - Ste-Foy

Trial Details

FieldValue
Enrollment Target 194 participants
Start Date 2022-08-11
Est. Completion 2026-11-02
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05061134

The ClinicalTrials.gov registry entry for NCT05061134 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 194 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (73% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Durvalumab is the first listed.

NCT05061134 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, California, Ontario.

Frequently Asked Questions

What is clinical trial NCT05061134 about?

NCT05061134 is a clinical study titled "A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition". Main study: This is an open-label, phase 2 study that aims to evaluate the efficacy and safety/tolerability of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma and primary or secondary resistance to PD-(L)1 inhib...

What is the current status of trial NCT05061134?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 194 participants. The study started on 2022-08-11. Estimated completion is 2026-11-02.

What conditions does trial NCT05061134 study?

This clinical trial studies the following conditions: Melanoma.

What interventions are being tested in trial NCT05061134?

The interventions under investigation include: Durvalumab (BIOLOGICAL), Ceralasertib (DRUG).

Who is sponsoring clinical trial NCT05061134?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05061134 being conducted?

This trial has 20 study locations across California, Florida, Maryland, Tennessee, Alberta. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Melanoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.